吡格列酮对早期糖尿病肾病患者血清CRP和IL-6水平的影响

Effects of Pioglitazone on the Serum CRP and IL-6 Levels in Early Patients with Diabetic Nephropathy

为探讨吡格列酮治疗早期糖尿病肾病(糖尿病肾病)的疗效,用免疫比浊法和R IA法测定糖尿病肾病患者血清CRP和IL-6水平。结果表明经吡格列酮治疗20例糖尿病肾病组患者血清CRP和IL-6水平较对照组和DM组显著升高(P<0.01),而且吡格列酮治疗前、后两组患者CRP和IL-6水平有显著性差异(P<0.05)。可见吡格列酮对糖尿病肾病患者治疗有效。

To study the effective treatment of pioglitazone in early patients with diabetes nephropathy （ DN）, the serum CRP and IL-6 levels in DN and DM patients were tested by RIA. The results showed that the serum levels of CRP and IL-6 in DN patients were higher than that in DM group and control group（P 〈0.01 ）. The serum CRP and IL-6 levels in DN patients were a significant reduction. There was a significant difference in serum CRP and IL-6 levels in patients before and after treatment with pioglitazone （ P 〈 0.05 ）. Pioglitazone may have significantly treatment effect in DN patients.